Nanotechnology based approaches for detection and delivery of microRNA in healthcare and crop protection

Table 2 Present scenario of miRNA therapeutics

Company	Targeted miRNA	Disease	Technology	Status
Regulus Therapeutics	miR-122	Hepatitis C	Anti-miR	Preclinical
	miR-10b	Glioblastoma	Anti-miR	Preclinical
	miR-221	HCC	Anti-miR	Preclinical
	miR-21	Renal fibrosis	Anti-miR	Preclinical
	miR-33	Atherosclerosis	Anti-miR	Completed preclinical
	miR-17	Autosomal dominant polycystic kidney disease	Anti-miR	Preclinical
	miR-27	Cholestatic disease	Anti-miR	Discontinued
	miR103/107	Type-II diabetes	Anti-miR	Phase-I
Santaris Plasma	miR-122	Hepatitis C	Anti-miR	Phase-IIa
Mirna therapeutics	miR-34	Primary liver cancer	Mimic	Phase-I
	miR-155	Hematological malignancies	Anti-miR	Completed preclinical
	miR-215	Cancer	Mimic	Preclinical
	miR-101	Cancer	Mimic	Preclinical
	miR-16	Cancer	Mimic	In pipeline
	let-7	Cancer	Mimic	In pipeline
miRagen therapeutics	miR-92	Peripheral artery disease	Anti-miR	Preclinical
	miR-15/195	Myocardial infarction	Anti-miR	Preclinical
	miR-155	Cutaneous T-cell lymphomas	Inhibition	Phase-I
	miR-208	Chronic heart failure	Inhibition	In pipeline
	miR-143/145	Vascular disease	Inhibition	In pipeline
	miR-29	Cardiac fibrosis	Inhibition	In pipeline
	miR-451	Abnormal red blood cell production	Anti-miR	Discovered
	miR-92	Peripheral arterial disease	Inhibition	In pipeline

ISSN: 1477-3155